Scaboma Lotion

Quick links

Choose a section

Quick links to important sections

Advertisements

Scaboma Lotion

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Scaboma Lotion

Scaboma Lotion is a prescription topical anti-parasitic medication manufactured by Glenmark Pharmaceuticals Ltd. (India). It is primarily used for the treatment of infestations caused by external parasites, specifically scabies (caused by mites) and pediculosis (head or body lice).

Quick Facts Description
Active Ingredient Gamma Benzene Hexachloride (Lindane) 1% w/v
Form Topical Lotion (External Use Only)
Pharmacological Class Organochlorine Pesticide, Ectoparasiticide
Primary Use Treatment of Scabies and Pediculosis
Designated Line of Therapy Second-line treatment (Rx)

The active component is Gamma Benzene Hexachloride, which is more commonly known as Lindane. This compound is classified as an ectoparasiticide and ovicide, meaning it is designed to kill external parasites as well as their eggs, providing a comprehensive treatment for infestation.

It is important for patients and prescribers to recognize the official positioning of this product. Lindane lotion is designated as a second-line therapy. This means its use is typically reserved for individuals who have either failed to respond to, or cannot tolerate, safer first-line treatments for scabies. Due to the potential for neurological toxicity, the use of this medicine is restricted in certain patient populations and requires strict adherence to the prescribed application protocol.

Advertisements

What side effects are possible with Scaboma Lotion?

Possible Side Effects and Safety Information

The safety profile of Scaboma Lotion (Lindane) is characterized by the potential for serious, yet rare, systemic effects, which is why regulatory authorities typically designate it as a second-line treatment. The officially documented adverse reactions are categorized by their frequency and the body systems they affect.

Systemic and Serious Adverse Reactions

The most serious safety consideration documented in regulatory labeling is the risk of neurotoxicity. This includes the potential for seizures (convulsions) and, in rare instances, death. These effects are classified as rare, but have been reported following repeat or prolonged application, and rarely after a single, directed application. Reactions affecting the Nervous System may also include dizziness, headache, paresthesia, and uncontrolled tremor.

Common and Expected Reactions

The most commonly reported adverse reactions are local effects affecting the Skin and Subcutaneous Tissues. These are generally associated with topical application and include: itching (pruritus), a burning sensation, dry skin, and a skin rash. Other listed dermatological effects include dermatitis and alopecia.

Population-Specific Safety Constraints

Official safety documents place strict constraints on use in certain vulnerable populations due to increased risk of systemic absorption and subsequent neurotoxicity. Scaboma Lotion is contraindicated in premature infants, individuals with uncontrolled seizure disorders, and patients with extensive skin conditions (e.g., crusted scabies) that may increase drug absorption. Use requires increased caution in infants, children, older adults, and individuals weighing less than 50 kg.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory information for Lindane 1% Lotion is explicitly defined by the potential for serious Neurotoxicity and systemic absorption, especially following misuse or accidental ingestion. The overdose profile is focused on central nervous system (CNS) effects and mandated emergency responses.

Domain Official Regulatory Statements
Documented Manifestations Clinical signs include CNS effects such as seizures (convulsions), vomiting, dizziness, drowsiness, uncontrolled body shaking, headache, muscle cramps, and paresthesia.
Severe Outcomes Regulatory warnings document the potential for death and severe systemic events like cardiac arrhythmia and pulmonary edema (reported in severe cases).
Vulnerable Populations The risk of serious neurotoxicity is documented to be higher in infants, children, the elderly, individuals weighing less than 50 kg, and those with pre-existing skin conditions (e.g., crusted scabies, psoriasis).

Required Emergency Actions

Immediate medical attention is mandated under specific, severe conditions. Seek emergency help right away if a seizure occurs during or after application. Call the Poison Control Center immediately if the lotion is accidentally swallowed or gets in the mouth, or if the individual has collapsed or is experiencing trouble breathing.

Management for confirmed overdose is limited to symptomatic and supportive treatment, including measures to control seizures and decontaminate the skin, as no specific antidote is known. Hospital monitoring may be required, reflecting the seriousness of the potential life-threatening events.

Advertisements

Therapeutic Uses of Scaboma Lotion

The therapeutic role of Scaboma Lotion is defined by the clinical management of persistent parasitic infestations, offering supportive symptom relief when initial treatments have not been successful. It serves as a second-line therapeutic option.

Targeting Persistent Ectoparasitic Infections

This treatment is used for active infestations by the scabies mite or lice (pediculosis), which are conditions involving symptoms related to inflammatory or irritative states. As a second-line option, it is applied when patients have not responded to other approved therapies or cannot tolerate alternative medications. The goal is to address the parasitic burden by targeting active parasites and their eggs, addressing the source of the infestation.

Relief from Intense Pruritus and Skin Manifestations

The medication is relevant for easing symptoms related to physical discomfort, particularly severe, persistent itching (pruritus) and the localized inflammatory skin rash caused by the parasites. When applied in situations involving significant discomfort, the treatment contributes to improved comfort during periods of heightened symptoms. It assists with maintaining stability when symptoms are most noticeable.

Support in Second-Line Treatment Scenarios

This reserved use is applied in settings involving acute or unstable symptom patterns and is relevant when supportive management is appropriate following therapeutic failure. It may be part of symptomatic management, supporting patients by easing distress and helping them manage symptom fluctuations more steadily.

Quick Fact Description
Symptom Domain Helps manage symptoms related to inflammatory or irritative states, specifically severe pruritus.
Context of Use Reserved for second-line management when initial treatments have failed or are not tolerated.
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Scaboma Lotion?

Scaboma Lotion (Lindane 1%) is designated by regulatory authorities as a second-line therapy. This means it should be used only by patients who have failed or cannot tolerate safer, alternative treatments.

Populations Contraindicated (Must Not Use)

The medicine is contraindicated and must not be used by specific high-risk patient groups due to the potential for serious neurotoxicity:

  • Premature Infants (neonates).
  • Individuals with an uncontrolled seizure disorder (epilepsy).
  • Patients with crusted (Norwegian) scabies or other conditions that compromise the skin barrier, such as extensive atopic dermatitis or psoriasis.
  • Individuals with a known hypersensitivity to Lindane or any components of the lotion.

Age-Related and Conditional Eligibility

Population Group Regulatory Status
Infants and Children (< 110 lbs / 50 kg) Use with caution; at greater risk of serious neurotoxicity.
Older Adults (Geriatric) Use with caution; at greater risk of serious neurotoxicity.
Pregnancy Not recommended; use only if clearly necessary.
Lactation Not recommended; breastfeeding must be interrupted for at least 24 hours after use.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Scaboma Lotion (Lindane) is structured by documented interactions that influence its systemic absorption and neurological effects.

Pharmacodynamic Interactions

Co-administration with other medicinal products known to lower the seizure threshold is associated with an increased risk of seizure. This includes official cautions regarding classes such as antipsychotics, antidepressants, and substances like theophylline. This additive effect is noted in government labeling as a clinically significant interaction risk.

Exposure-Modifying Substances and Administration Constraints

The co-application of oil-based products, such as certain creams and ointments, is documented to significantly enhance the percutaneous absorption of Lindane. This pharmacokinetic interaction results in higher systemic drug exposure, increasing the potential for neurotoxicity.

Interaction Type Interacting Substance/Condition Official Regulatory Outcome
Topical Absorption Oil-based products Increased systemic exposure; increased seizure risk
Timing Constraint Wet or warm skin from bathing/showering Mandatory waiting period until skin is cool and dry

Population-Specific Interaction Considerations

Specific patient conditions are explicitly noted to heighten the risk of severe interaction. These include individuals with a history of head trauma, CNS tumor, severe hepatic cirrhosis, and conditions associated with excessive alcohol use.

Advertisements

Mechanism of Action

How Scaboma Lotion Works at the Biological Level

The action of Scaboma Lotion is driven by two distinct pharmacodynamic mechanisms: neurotoxicity and membrane disruption.

Disruption of Parasite Nervous System

The primary active component, Permethrin, functions as a modulator of voltage-gated sodium channels within the nerve membranes of target arthropods (mites and lice). This interaction inhibits the channels from undergoing normal inactivation and closing, leading to persistent membrane depolarization and signal hyper-excitation. The resulting downstream cascade is massive, uncoordinated nerve firing, which produces neurological failure and rapid paralysis and mortality in the parasites.


Surface Membrane Disruption and Antiseptic Action

The second component, Cetrimide, functions as a cationic surfactant that acts on the cell membranes of surface bacteria and fungi. It physically disrupts the membrane integrity, causing increased permeability and subsequent leakage of essential intracellular components. This mechanism results in a localized antiseptic effect that controls secondary microbial proliferation in areas of compromised skin integrity.

Advertisements

Dosage and Administration Information

Scaboma Lotion (Lindane 1% w/v) is a medication for topical administration, applied solely to the skin for external use. The treatment course is a single application, which is non-repeatable.

The administration procedure consists of specific adherence to both coverage and quantity. A thin layer of the lotion must be applied to all skin areas from the neck down. The typical quantity for an average adult is one ounce (approximately 30 mL), and the maximum quantity for larger individuals should not exceed two ounces (approximately 60 mL). The lotion quantity dispensed is limited to this single course and is not intended to be saved or reused.

Before application, the skin must be clean, dry, and entirely free of any other topical products, such as oils, creams, or lotions. The procedural instruction dictates that the application must remain on the skin for a duration of 8 to 12 hours. After this time-bound window, the lotion must be thoroughly washed off using warm water to finalize the treatment course. The use of this lotion is intended for adults and children who meet a minimum body weight of 110 pounds (50 kg).

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Scaboma Lotion

Evidence Base for Scabies Treatment

Research examining Lindane (the active component in Scaboma Lotion) has primarily been conducted through Randomized Controlled Trials (RCTs) and Systematic Reviews evaluating its use alongside other anti-parasitic agents. These studies were used in research exploring how symptoms change over time in conditions characterized by fluctuating or episodic manifestations. Study populations included adults and children who had received a diagnosis of scabies, including those where symptoms may vary in intensity or where a previous treatment had not achieved clearance.

Research examined outcomes related to physical discomfort, such as the total clearance of the mite infestation and outcomes monitoring physiological strain or stress, specifically the persistent and severe itching known as pruritus. Comparative trials monitored whether the measured clearance rates were compared to those observed with some alternative treatments.

Study Focus on Symptom Resolution (Pruritus)

Studies monitored the patient-reported outcomes describing perceived discomfort, specifically focusing on the severe itching associated with the condition. Findings help contextualize how patients reported their experience, showing that for some individuals, the symptom of pruritus was observed to persist for a period of time, relative to when the studies reported the underlying infestation had been cleared.

Evidence Base for Pediculosis (Lice) Treatment

The research available for Lindane in the context of pediculosis (lice) treatment was evaluated in Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies explored short-term symptom changes and outcomes linked to inflammatory or irritative states. Studies monitored the eradication of both living lice and their eggs (ovicidal activity) in populations that included children and adults with active infestations of head or pubic lice.

Data show patterns related to eradication rates, with some trials indicating that outcomes were measured as different when compared to certain other treatments for lice. Furthermore, studies monitored the necessary duration of contact, with some evidence describing patterns of activity and ovicidal rates that were compared to some alternatives.

Remaining Uncertainties and Research Gaps

Long-term effects are not fully established as the evidence base for Scaboma Lotion relies mainly on short-term follow-up data. Key limitations include the mixed findings reported across various studies and the recognized issue of resistance, which varies globally. The overall evidence quality is noted by researchers to vary across studies due to differences in methodology and the lack of standardization in older trials. Research exploring short-term symptom changes only provides context about outcomes related to physical discomfort observed during the initial period of study.

Key Studies & References

  1. Treatment of ectoparasitic infections: review of the English-language literature, 1982-1992
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Scaboma Lotion (FAQ)


Q: Is Scaboma Lotion the same as other anti-itch lotions?

Scaboma Lotion is described in official documentation as a prescription topical anti-parasitic medicine (or ectoparasiticide) used to treat specific parasitic infestations. This classification distinguishes it from general over-the-counter anti-itch products, which are typically used only for symptom relief rather than addressing the underlying parasitic cause.


Q: What's the typical time frame before a person might notice a change after using the lotion?

Regulatory documents indicate the active ingredient is intended for a rapid action against target mites and lice. However, official information describes that the intense itching, known as pruritus, is often an allergic reaction to the infestation. Because of this, the itching may persist for several weeks after the drug has successfully cleared the parasites, which is not considered a sign of treatment failure.


Q: Do people typically experience a burning sensation when applying Scaboma Lotion?

Yes, regulatory documents list a burning sensation on the skin as one of the most commonly reported side effects following topical application. This local reaction is commonly reported in association with the medication.


Q: Is it normal if the itching seems worse right after the first use?

Official patient information notes that the itching may sometimes appear worse after using the medicine. However, this observation does not necessarily indicate that the treatment has failed. Official documentation reminds patients not to reapply the lotion. It also indicates that other medications may be used to help manage the persistent itch.


Q: What kind of studies have been done on Scaboma Lotion's effectiveness?

The evidence base for the active ingredient, Lindane, is rooted in research primarily conducted through Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies evaluated clearance rates for both scabies and lice, often comparing the results against alternative treatments.


Q: Are there any specific cosmetic products that might interact with Scaboma Lotion?

Official documents advise avoiding all cosmetics and skincare products on the treated skin. Specifically, any products containing oils, including certain lotions, moisturizers, or hair products, are noted to enhance the drug’s absorption. Increased absorption raises the potential risk of systemic side effects, and these products should be avoided immediately before and after application.


Q: Is Scaboma Lotion generally safe for use by older adults?

Official labeling notes that older adults (geriatric patients) are at a greater risk of experiencing serious neurological toxicity. Therefore, the use of this medication in this population group requires increased caution.


Q: Is it okay to go swimming or take a shower shortly after applying Scaboma Lotion?

The official protocol requires the lotion to remain on the skin for a precise duration of 8 to 12 hours. As the product is intended for a single, time-bound application, exposure to water during this required treatment window may disrupt the protocol.


Q: Does Scaboma Lotion lose its potency if it's been open for a long time?

Regulatory guidance dictates that any unused or leftover lotion, along with the bottle, must be discarded immediately after use. Official guidance specifies that the product is not intended to be saved or reused for a later date.


Q: What research is available on using Scaboma Lotion in young children?

Official safety constraints state that the medicine is contraindicated (must not be used) in premature infants. For children who weigh less than 110 pounds (50 kg), the drug must be used with caution. This is because smaller children are at a greater risk of neurotoxicity due to potentially increased systemic absorption.


Q: Does using too much Scaboma Lotion make it work better?

Official warnings state that applying the drug in large amounts or for a longer time than recommended does not provide quicker or better results. Official warnings state that increased use raises the risk of serious side effects, such as neurotoxicity and seizures.


Q: How quickly is the active ingredient in Scaboma Lotion absorbed through the skin?

Official information does not specify a general absorption rate in a timeframe like minutes or hours. However, regulatory warnings note that absorption is significantly enhanced if the product is applied to skin that is wet, warm, or has been recently treated with oil-based products.


Q: Is Scaboma Lotion known to interact with common vitamin or mineral supplements?

Official documents advise consulting a healthcare provider before using any other medication, including over-the-counter medicines, vitamins, and herbal products. This warning is in place because some supplements may interact with the lotion by lowering the seizure threshold.


Q: Can the effectiveness of Scaboma Lotion be reduced by certain environmental factors?

Yes, official storage instructions require the product to be protected from freezing and kept away from excess heat. Adhering to these requirements is necessary to maintain the lotion's integrity and potency.


Q: Are there official warnings about applying Scaboma Lotion near mucous membranes?

Official administration instructions specify that the drug is for external use only. Patients are warned to avoid contact with the face, eyes, mouth, and any mucous membranes (such as the urinary opening) to prevent accidental systemic absorption and irritation.


Q: Does Scaboma Lotion require a specific type of cleaning or removal after the treatment period?

Official instructions specify that after the 8- to 12-hour period, the lotion must be thoroughly washed off using warm water. Some official documents further clarify that this process should use warm, soapy water to ensure complete removal from the skin.


Q: Are there any studies focusing on the long-term use of Scaboma Lotion?

The evidence base for Scaboma Lotion's active ingredient relies mainly on data collected over short-term follow-up periods. Official documents explicitly state that the long-term effects of using the product are not fully established.


Q: Can Scaboma Lotion be used on the face or scalp?

Official instructions for the treatment of scabies specify applying the lotion to all skin areas from the neck down. The instructions state that the lotion should not be used on the face or scalp for this indication.


Q: Why do official documents mention consulting a healthcare provider if the condition persists?

Official information instructs the patient to seek professional advice if the condition is still present after one week. This is because persistent symptoms may indicate true treatment failure rather than simply persistent post-treatment itching, which requires different management.


Q: What is the relationship between the active ingredient and similar drugs used for the same purpose?

The active ingredient, Lindane, is officially designated as a second-line therapy for its primary uses. This means that its use is generally reserved for individuals who have either failed to respond to, or cannot tolerate, alternative first-line treatments that are considered safer.


Q: Does alcohol consumption have any reported effects or interactions with Scaboma Lotion?

Official documents explicitly advise patients to consult a doctor before drinking alcohol while using this medicine. This is because individuals with a history of excessive alcohol use are listed as being at increased risk for severe interaction and neurotoxicity.


Q: What is the common reason for treatment failure associated with Scaboma Lotion?

Official warnings strongly prohibit using the product more than once, as re-treatment can cause serious neurotoxicity. In addition to improper application, a key research concern noted in official reports is the recognized issue of parasitic resistance, which is documented to vary globally.


Q: Is Scaboma Lotion effective against all stages of the relevant parasitic infection?

Official documentation describes the active component as an ectoparasiticide and ovicide. This means it is designed to be effective against both the external adult parasites (mites or lice) and their eggs.


Q: What are the restrictions on using Scaboma Lotion if a person has certain pre-existing skin conditions?

The medicine is strictly contraindicated (must not be used) in patients with crusted (Norwegian) scabies. It is also contraindicated for patients with other extensive skin conditions, such as atopic dermatitis or psoriasis, which could compromise the skin barrier and significantly increase drug absorption.


Q: Do the official instructions mention anything about washing clothing or bedding after use?

Official public health guidelines associated with Lindane treatment recommend environmental control measures. These include washing all bedding, towels, and recently worn clothes in hot water or having them professionally dry cleaned.


Q: How do I know if the Scaboma Lotion I have is expired?

Official guidance requires the product to be kept at controlled room temperature and protected from freezing. Unused or expired medication should never be saved. Regulatory authorities require that any leftover or expired medicine be disposed of immediately through designated drug take-back or hazardous waste programs.

Advertisements

How should Scaboma Lotion be stored and disposed of?

How to Store and Dispose of Scaboma Lotion?

The storage and disposal of Scaboma Lotion, which contains Lindane, must adhere to specific regulatory guidelines to maintain product integrity and prevent harm.


Storage Requirements

Requirement Official Condition
Temperature Store at Controlled Room Temperature (typically 15 C to 30 C).
Protection Keep from freezing and away from excess heat and moisture.
Container Keep the container tightly closed and store out of the reach of children.

Disposal Instructions

Any unused or leftover lotion, along with the bottle, must be discarded immediately after use; do not save it for later. Disposal must not occur in the drain or the toilet due to the environmental classification of Lindane. Disposal should utilize designated channels, such as drug take-back programs or hazardous waste collection programs, as directed by official authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Scaboma Lotion found in:

A-Z Index: